Shanghai MicroPort Endovascular MedTech Co., Ltd.

XSSC:688016 Stock Report

Market Cap: CN¥12.6b

Shanghai MicroPort Endovascular MedTech Valuation

Is 688016 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688016 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688016 (CN¥103.04) is trading above our estimate of fair value (CN¥102.68)

Significantly Below Fair Value: 688016 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688016?

Key metric: As 688016 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688016. This is calculated by dividing 688016's market cap by their current earnings.
What is 688016's PE Ratio?
PE Ratio19.2x
EarningsCN¥657.34m
Market CapCN¥12.61b

Price to Earnings Ratio vs Peers

How does 688016's PE Ratio compare to its peers?

The above table shows the PE ratio for 688016 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.3x
688029 Micro-Tech (Nanjing)Ltd
24.6x19.0%CN¥13.3b
301371 Harbin Fuerjia Technology
20.3x8.4%CN¥14.6b
300595 Autek China
25.9x16.8%CN¥16.4b
600529 Shandong Pharmaceutical GlassLtd
18.4x18.4%CN¥16.0b
688016 Shanghai MicroPort Endovascular MedTech
19.2x20.3%CN¥12.6b

Price-To-Earnings vs Peers: 688016 is good value based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (21.9x).


Price to Earnings Ratio vs Industry

How does 688016's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
688016 19.2xIndustry Avg. 34.6xNo. of Companies18PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688016 is good value based on its Price-To-Earnings Ratio (19.2x) compared to the CN Medical Equipment industry average (35x).


Price to Earnings Ratio vs Fair Ratio

What is 688016's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688016 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.2x
Fair PE Ratio27.4x

Price-To-Earnings vs Fair Ratio: 688016 is good value based on its Price-To-Earnings Ratio (19.2x) compared to the estimated Fair Price-To-Earnings Ratio (27.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688016 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥103.04
CN¥132.14
+28.2%
24.4%CN¥185.72CN¥86.00n/a5
Nov ’25CN¥98.06
CN¥130.14
+32.7%
27.1%CN¥185.72CN¥76.00n/a5
Oct ’25CN¥113.00
CN¥130.14
+15.2%
27.1%CN¥185.72CN¥76.00n/a5
Sep ’25CN¥86.25
CN¥155.12
+79.8%
13.5%CN¥185.72CN¥120.00n/a5
Aug ’25CN¥98.89
CN¥162.79
+64.6%
7.2%CN¥185.72CN¥154.36n/a5
Jul ’25CN¥97.80
CN¥162.79
+66.5%
7.2%CN¥185.72CN¥154.36n/a5
Jun ’25CN¥112.89
CN¥157.01
+39.1%
1.5%CN¥160.27CN¥154.36n/a4
May ’25CN¥125.11
CN¥159.32
+27.3%
3.4%CN¥169.21CN¥154.36n/a5
Apr ’25CN¥126.19
CN¥159.32
+26.2%
3.4%CN¥169.21CN¥154.36n/a5
Mar ’25CN¥127.18
CN¥159.99
+25.8%
3.1%CN¥169.21CN¥154.36n/a5
Feb ’25CN¥107.62
CN¥159.99
+48.7%
3.1%CN¥169.21CN¥154.36n/a5
Jan ’25CN¥130.62
CN¥160.39
+22.8%
3.4%CN¥169.21CN¥154.36n/a4
Dec ’24CN¥138.91
CN¥160.39
+15.5%
3.4%CN¥169.21CN¥154.36n/a4
Nov ’24CN¥129.32
CN¥160.39
+24.0%
3.4%CN¥169.21CN¥154.36CN¥98.064
Oct ’24CN¥124.42
CN¥162.40
+30.5%
3.0%CN¥169.21CN¥157.72CN¥113.003
Sep ’24CN¥115.62
CN¥164.06
+41.9%
3.9%CN¥170.40CN¥157.72CN¥86.252
Aug ’24CN¥115.62
CN¥164.06
+41.9%
3.9%CN¥170.40CN¥157.72CN¥98.892
Jul ’24CN¥120.72
CN¥164.06
+35.9%
3.9%CN¥170.40CN¥157.72CN¥97.802
Jun ’24CN¥108.05
CN¥164.06
+51.8%
3.9%CN¥170.40CN¥157.72CN¥112.892
May ’24CN¥116.24
CN¥167.08
+43.7%
5.6%CN¥176.44CN¥157.72CN¥125.112
Apr ’24CN¥115.67
CN¥167.08
+44.4%
5.6%CN¥176.44CN¥157.72CN¥126.192
Feb ’24CN¥146.30
CN¥166.44
+13.8%
4.8%CN¥174.50CN¥158.39CN¥107.622
Jan ’24CN¥126.87
CN¥166.44
+31.2%
4.8%CN¥174.50CN¥158.39CN¥130.622
Dec ’23CN¥128.33
CN¥166.44
+29.7%
4.8%CN¥174.50CN¥158.39CN¥138.912
Nov ’23CN¥145.97
CN¥166.44
+14.0%
4.8%CN¥174.50CN¥158.39CN¥129.322

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies